May 18, 2026 08:30 ET | Source: Teva Pharmaceutical Industries Ltd TEL AVIV, Israel, May 18, 2026 (GLOBE NEWSWIRE) — Teva Pharmaceutical Industries Ltd. (NYSE and TASE: TEVA) today announced that Fitch Ratings Agency (“Fitch”) has raised the Company’s corporate credit rating to Investment Grade BBB-, with a stable outlook, from BB+. “This strong endorsement, our third […]
May 18, 2026 08:00 ET | Source: Teva Pharmaceutical Industries Ltd PARSIPPANY, N.J. and TEL AVIV, Israel, May 18, 2026 (GLOBE NEWSWIRE) — Teva Pharmaceuticals, a U.S. affiliate of Teva Pharmaceutical Industries Ltd. (NYSE and TASE: TEVA), today announced new data from the ongoing, real-world IMPACT-TD Registry, highlighting a significant gap in diagnosing tardive dyskinesia (TD) in
May 18, 2026 04:00 ET | Source: Royal Philips May 18, 2026 Philips-led consortium selected through Karolinska University Hospital-led Region Stockholm tender to deliver advanced remote monitoring for complex patients Stockholm, Sweden – Royal Philips (NYSE: PHG, AEX: PHIA), a global leader in health technology, today announced that a consortium composed of Philips, Cuviva and Vingmed has been selected
May 18, 2026 02:00 ET | Source: Boehringer Ingelheim Limited Not intended for UK and US audiences Boehringer Ingelheim today announced that Japan’s Ministry of Health, Labour and Welfare (MHLW) has approved JASCAYD® (nerandomilast) for the treatment of adults with idiopathic pulmonary fibrosis (IPF) and adults with progressive pulmonary fibrosis (PPF). It is the first phosphodiesterase 4B (PDE4B) inhibitor
May 14, 2026 16:05 ET | Source: Zymeworks Inc. VANCOUVER, British Columbia, May 14, 2026 (GLOBE NEWSWIRE) — Zymeworks Inc. (Nasdaq: ZYME), a biotechnology company managing a portfolio of licensed healthcare assets while developing a diverse pipeline of novel, multifunctional biotherapeutics, today announced that its Board of Directors has authorized a 2026 share repurchase program under which
Investigational New Drug application for KHN921 received “study may proceed” from the US FDA. KHN921 is a potential “first-in-class” cardiovascular AAV gene therapy being developed for the treatment of hypertrophic cardiomyopathy (HCM) associated with MYBPC3 mutations May 13, 2026 14:09 ET | Source: Vanotech Ltd CHENGDU, China and ROCKAWAY, N.J., May 13, 2026 (GLOBE NEWSWIRE) — Chengdu
The presentation will examine PPWR minimization-driven blister innovations, including recyclable and recycled pharmaceutical grades. Company will also showcase its advanced barrier materials and expanded multidose vial capabilities May 13, 2026 10:22 ET | Source: TekniPlex Wayne, PA, May 13, 2026 (GLOBE NEWSWIRE) — TekniPlex Healthcare, which utilizes advanced materials science expertise to help deliver better patient outcomes, will exhibit and present at The Pharma Days
May 13, 2026 09:41 ET | Source: Sabin Vaccine Institute WASHINGTON, May 13, 2026 (GLOBE NEWSWIRE) — The 2026 Sabin Awards were presented yesterday at the National Academy of Sciences building in Washington, D.C., with Professor Uğur Şahin, MD, and Professor Özlem Türeci, MD, receiving the Sabin Vaccine Institute’s Albert B. Sabin Gold Medal for their role
May 13, 2026 06:00 ET | Source: Zymeworks Inc. VANCOUVER, British Columbia, May 13, 2026 (GLOBE NEWSWIRE) — Zymeworks Inc. (Nasdaq: ZYME), a biotechnology company managing a portfolio of licensed healthcare assets while developing a diverse pipeline of novel, multifunctional biotherapeutics, today announced that management will participate in the following upcoming investor conferences: About Zymeworks Inc. Zymeworks
May 12, 2026 08:30 ET | Source: Adagene Inc. SAN DIEGO and SUZHOU, China, May 12, 2026 (GLOBE NEWSWIRE) — Adagene Inc. (“Adagene or the Company”) (Nasdaq: ADAG), a company transforming the discovery and development of novel antibody-based therapies, today announced that senior management will participate in one-on-one investor meetings and a fireside chat at the Stifel Annual Virtual
May 12, 2026 08:05 ET | Source: Boehringer Ingelheim Limited Ingelheim, Germany and Waltham, Mass., U.S., May X, 2026 – Boehringer Ingelheim and Immunitas Therapeutics today announced a global licensing agreement for a preclinical antibody program being developed for chronic inflammatory and autoimmune diseases. The program is designed to selectively target cells that play a central role in
May 11, 2026 21:32 ET | Source: Enlitic LOVELAND, Colo., May 11, 2026 (GLOBE NEWSWIRE) — Enlitic, a global leader in radiology and imaging data, today announced the successful go-live of its Ensight platform at RHCNZ Medical Imaging Group (RHCNZ), New Zealand’s largest private radiology provider. The deployment marks Enlitic’s first customer in New Zealand and represents
May 11, 2026 08:00 ET | Source: AskBio Inc. (AskBio) Durham, N.C., May 11, 2026 (GLOBE NEWSWIRE) — AskBio Inc. (AskBio), a gene therapy company wholly owned and independently operated as a subsidiary of Bayer AG, today announced that the first participant has been dosed with investigational gene therapy AB-1009 as part of PROGRESS-GT LOPD, a Phase 1/Phase 2 clinical trial in participants with late-onset Pompe disease (LOPD). LOPD
May 11, 2026 07:00 ET | Source: Dark Horse Consulting Group WALNUT CREEK, Calif., May 11, 2026 (GLOBE NEWSWIRE) — Dark Horse Consulting Group (“DHCG” or “the Group”), a leader in strategic and operational biotherapeutics consulting, and KunTuo Medical Research and Development (Beijing) Co., Ltd. (“KunTuo”), a full-service contract research organization (CRO) dedicated to clinical research services
May 11, 2026 05:00 ET | Source: BASF Agricultural Solutions Ludwigshafen, Germany, May 11, 2026 – BASF Agricultural Solutions has successfully commissioned its BioHub, a new fermentation plant for biological and biotechnology-based crop protection products, at the Ludwigshafen site. With an investment in the high double-digit million-euro range, BASF is strengthening its portfolio of biological innovations. The
